If p53 alterations occur frequently in relapse, or if chemoresistance is associated with loss of p53 function, the use of chemotherapeutic agents in neuroblastoma that either do not depend on the presence of a functional p53 (taxol, ceramide modulators, BSO/L-PAM) or are more effective if TP53 is inactivated would be highly recommended [15,37]. This evidence concerns the gene TP53 and neuroblastoma.